Royalty Pharma RPRX EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on the most recent quarter.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's EV / EBITDA?
- Royalty Pharma (RPRX) reported EV / EBITDA of 13.9× in Q4 2024.
- How has Royalty Pharma's EV / EBITDA changed year-over-year?
- Royalty Pharma's EV / EBITDA increased by 14.3% year-over-year, from 12.2× to 13.9×.
- What does EV / EBITDA mean?
- What the whole business (debt included) costs relative to its operating cash earnings.
- How do you interpret EV / EBITDA?
- Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
- How does EV / EBITDA compare across companies?
- Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.